Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28748529 | 1.00 | LTA4H (0.36) | LTA4HFAAHALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL30948675 | 0.89 | FAAH (0.33) | FAAHALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18476646 | 0.85 | FAAH (0.38) | FAAHALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18452613 | 0.85 | FAAH (0.38) | FAAHALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18452721 | 0.84 | FAAH (0.34) | FAAHCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30948652 | 0.83 | LTA4H (0.38) | LTA4HFAAHCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30948764 | 0.80 | TDP1 (0.32) | FAAHCYP1A2CYP2C9CYP2C19 | |
| 6-Diazo-5-Oxo-L-Norleucine SCHEMBL295053 | 0.79 | GSR (0.52) | ALDH1A1CYP1A2SLC1A1 | |
| 6-Diazo-5-Oxo-L-Norleucine SCHEMBL4281654 | 0.79 | GSR (0.52) | ALDH1A1CYP1A2SLC1A1 | |
| 6-Diazo-5-Oxo-L-Norleucine SCHEMBL9295 | 0.79 | GSR (0.52) | ALDH1A1CYP1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577201-B2 | Glutamine analogs | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| EP-4229029-B1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2026-02-25 | — | — | EP | disclosed |
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2023202652-A9 | PHARMACEUTICAL COMBINATION AND USE THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023202652-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | WO | disclosed |
| EP-4229029-A1 | NOVEL GLUTAMINE ANALOGS | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022078416-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022078462-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577201-B2 | Glutamine analogs | GLUL, GLS, GLS2 | LTA4H 1608/4885FAAH 1840/4885ALDH1A1 3142/4885 |
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | GLUL, GLS, GLS2 | LTA4H 1011/4885FAAH 1065/4885ALDH1A1 971/4885 |
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | LTA4H 1962/4885FAAH 840/4885ALDH1A1 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.